NanoViricides

NNVC

Market cap $24.4M

NanoViricides (NYSE-A:NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, has highlighted the current influenza season as an example of the need for antivirals capable of targeting multiple respiratory viruses. The US Centers for Disease Control and Prevention (CDC) has classified the 2025 to 2026 flu season as “moderately severe,” with the Influenza A/H3N2 subclade K responsible for more than 80% of cases.

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, declares that the current severe influenza wave demonstrates the clear need for broad-spectrum antivirals that can work against all influenza viruses, as well as the seasonal respiratory viruses including RSV and Coronaviruses. This year has been a "moderately severe" flu season according to CDC.

NanoViricides (NYSE-A:NNVC) is gearing up to tackle multiple viral threats with Phase 2 trials for its broad-spectrum antiviral NV-378, as analysts at Alliance Global Partners kick off coverage with a Buy rating and $6 price target. The biotechnology company, which is developing innovative antiviral therapies, is advancing its lead candidate NV-378 into Phase 2 trials next year, targeting a range of viral infections including Mpox, influenza, COVID-19, and respiratory syncytial virus (RSV), according to analysts at Alliance Global Partners.

Speculative investors and patience rarely go hand in hand. Nevertheless, if you're looking to invest in the small-cap biotech sector, patience is a requirement.

NanoViricides (NYSE-A:NNVC) said on Monday it signed a master services agreement with regulatory consulting firm Only Orphans Cote LLC to support the company's orphan drug strategy for its broad-spectrum antiviral candidate NV-387. The firm, founded by former US Food and Drug Administration official Dr Timothy Cote, will help develop and prosecute orphan drug designation applications for NV-387 at the FDA's Office of Orphan Products, NanoViricides said.

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has signed a Master Services Agreement (MSA) with Only Orphans Cote, LLC, ("OOC") a regulatory consultant firm founded by Dr. Timothy Cote.

NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for monkeypox in Central Africa. In its quarterly report for the quarter ended September 30, 2025, the clinical-stage biotech company said NV-387 is engineered to resist viral escape.

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange Commission (SEC) on Friday, November 14, 2025.

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Friday, November 14th, at 11:25am ET at the Pharma Partnering Summit 2025 held at the Hilton Boston Logan Airport in Boston, MA. Event Information: Event NanoViricides Presentation at the Pharma Partnering Summit 2025 in Boston, MA Time & Date 11:25 am to 11:45 am ET on Friday, November 14, 2025 Location Hilton Boston Logan Airport, Boston, MA Anil R.

NanoViricides (NYSE-A:NNVC) said on Thursday it had closed a $6 million registered direct offering with a single healthcare institutional investor to support working capital and general corporate purposes. The Connecticut-based biotechnology company sold about 3.57 million shares of common stock, or equivalents, at $1.68 per share.